# ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

> **NCT03198507** · PHASE3 · COMPLETED · sponsor: **RedHill Biopharma Limited** · enrollment: 455 (actual)

## Conditions studied

- Helicobacter Pylori Infection
- Dyspepsia

## Interventions

- **DRUG:** RHB-105
- **DRUG:** Active Comparator

## Key facts

- **NCT ID:** NCT03198507
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-18
- **Primary completion:** 2018-10-24
- **Final completion:** 2018-12-13
- **Target enrollment:** 455 (ACTUAL)
- **Last updated:** 2020-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03198507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03198507, "ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03198507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*